Drug Profile

Poseltinib - Hanmi Pharmaceutical

Alternative Names: HM 71224; LY 3337641; NB-02 - NOBO Medicine

Latest Information Update: 18 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hanmi Pharmaceutical
Developer Eli Lilly and Company; Hanmi Pharmaceutical; NOBO Medicine
Class Antineoplastics; Antirheumatics; Piperazines; Pyrimidines; Small molecules
Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

11 Aug 2025 NOBO Medicine plans the phase I POTENTIAL-M trial for Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) (PO), in September 2025 (NCT07114367),
24 Dec 2024 https://325f0582.isolation.zscaler.com/profile/f1651b6c-5a7a-4e25-a61a-66f8cd23da60/zia-session/?tenant=2c2f6c39ed9e&region=bom&controls_id=e9deed71-abd6-47d6-beda-3be9a5b22af8&user=029860c8f97377a95a96735dfa6c1ffef3f348a3b26af33788a630663cd8a3d5&original_url=https%3A%2F%2Fwww.nobomedicine.com%2F%3Fpost_type%3Dnews&key=sh-1&hmac=4e7729c259a254c7adc380855fa1be2c77d135c351f3c224e3eba06850a0e19e -According to NOBO medicine pipeline, Hanmi and NOBO Medicine had a technology transfer deal between them but as there is no R found, only based on pipeline, org T was updated and this RDI was linked to the given trial (NCT06737250) - Trial initiation information added
25 Nov 2024 Phase-II clinical trials in Lymphoma (Second-line therapy or greater, Combination therapy) in South Korea (PO) (NCT06737250)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com